Regan et al. reviewed the preparation and considerations of MIPs for point-of-care testing for cardiovascular disease, focusing on protein biomarkers like cTnI, cTnT, myoglobin, and C-reactive protein (CRP) [15]. This evidence concerns the gene CRP and cardiovascular disorder.